Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Beam Therapeutics Inc. Director's Dealing 2021

Jul 1, 2021

31533_dirs_2021-06-30_170b621e-0ec6-473c-a236-b4b578a3d39e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2021-06-28

Reporting Person: Ciaramella Giuseppe (President & CSO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-28 Common Stock M 78580 $17.00 Acquired 123341 Direct
2021-06-28 Common Stock S 2405 $103.83 Disposed 120936 Direct
2021-06-28 Common Stock S 5464 $104.40 Disposed 115472 Direct
2021-06-28 Common Stock S 7040 $105.52 Disposed 108432 Direct
2021-06-28 Common Stock S 10444 $106.35 Disposed 97988 Direct
2021-06-28 Common Stock S 10829 $107.30 Disposed 87159 Direct
2021-06-28 Common Stock S 30369 $108.11 Disposed 56790 Direct
2021-06-28 Common Stock S 9856 $109.32 Disposed 46934 Direct
2021-06-28 Common Stock S 2173 $110.00 Disposed 44761 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-28 Stock Option (Right to Buy) $17.00 M 78580 Disposed 2030-02-05 Common Stock (78580) Direct

Footnotes

F1: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $104.96, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $105.98, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.97, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.99, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.90, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01, inclusive.

F11: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.